Neuropharmaceuticals Commercialization by Gaymalov, Zagit
11th Annual NanoBusiness Conference
Nanomanufacturing Summit 
September 4-6, 2012 
Boston, MA
© 2012 NeuroNano Pharma, Inc. All rights reserved.
neuronano pharma
-9oneuro TM
neuropharmaceuticals 
commericalization 
I. Introduction
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1. Problem: Global obesity epidemics
2. Unmet need: Safe and effective anti-obesity drug
3. Solution: leptiPOL™ - intranasal conjugated leptin 
formulation
4. Capital & time 
requirement $15M (up to 20X ROI, 7-10 years)
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II. Our Business Model
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leptiPOL™
customer
segments
relationship
channels
key
activities
key
resources
key 
partners
costs revenue streams
development 
of value proposition
innovation value - rightleft - innovation competence
patient
segments
We are a pharmaceutical company focused on development of leptin based anti-
obesity intranasal formulation
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III. Problem - Global Obesity Epidemics
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Obesity is not a personal 
choice, its a disease.
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•	Estimated annual obesity 
market size $1.7B. 
•	US population: 313M
•	EU popolation: 711M
IV. Current Treatment Options & Limitations
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1. Diet & Exercise Low compliance 
2. Supplements Unknown	efficacy	
3. OTD & Rx Drugs Unwanted side effects
4. Surgery High risks & costs
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V. Obesity Market Unmet Needs
-9oneuro TM 6
1.	Immediate	efficacy
2. Safety of chronic use
3. Ease of administration
4. Low side effects
5. Independence of diet and exercise
6. Wideness of safe dose range
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VI. Leptin Role in Obesity 
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Leptin is a hormone produced in adipose tissue. It lowers appetite and signals the 
body to burn fat.
In obese patients, 
receptor mediated 
leptin transport 
to the brain is 
impaired (leptin 
desensitization).
In healthy persons, 
leptin transported to 
the brain throught 
BBB, via leptin 
receptors
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VII. Leptin Hormone Based Drugs Evolution
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1990s
2000s
2010s
First generation:
naked leptin
Second generation:
PEGylated leptin
Third generation:
leptiPOL™
fragile, 
non-stable, 
short half-life,
low bioavalibility, 
does not cross BBB
stable, 
prolonged half-life
long shelf-life,
low bioavalibility, 
does not cross BBB
stable, 
prolonged half-life
long shelf-life,
high bioavalibility, 
cross BBB
© 2012 NeuroNano Pharma, Inc. All rights reserved.
VIII. leptiPOL™ - a Novel Leptin-Based Drug
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leptiPOL™ HM advantages:
•	Rapid brain delivery
•	Targeted hypothalamus delivery
•	Immediate effectiveness
•	Independence of diet and 
exercise
•	Convenience of intranasal 
delivery
•	Safety	(overdose,	fluctuation)
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IX. Preclinical Data
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Treatment with leptiPOL reduces food intake and body 
weight
LeptiPOL crosses blood brain barrier and reaches 
brain independent of leptin transporter
Intranasal administration is convenient and effective 
LeptiPOL starts working as early as 20 minutes after 
administration
What?
How?
When?
Other?
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X. Intellectual Property Porfolio 
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Extensive IP portfolio (over 30 patent and patent applications) 
exclusively licensed to NeuroNano Pharma
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X. Intellectual Property  Positioning 
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IP positions secured in United States and 
number	of	strategically	identified	countries:	
Europe, Japan, Australia, Canada, & Russia
Opinions on Freedom to Operate are in process
Branding strategy and implementation efforts 
has been initiated
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XI. Commercialization Pathway 
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PRE-CLINICAL DEVELOPMENT CLINICAL DEVELOPMENT
Formal
pre-clinical 
studies
Pre-IND 
Studies
CMC Package 
Pre-IND 
Studies
ADME-tox
Phase I
Clinical 
Trials
Phase II
Clinical
Trials
Phase “Seed”
up to $2M
Phase A
up to $5M
pre-IND
meeting 
up to $2M
Phase B Phase C
up to $6M
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
leptiPOL™ Obesity
Discovery Candidate
Selection
Pre-clinical
Research
Pre-clinical 
Development
Phase 1,2Product Indications
Out-Licensing Out-Licensing,
M&A
Out-Licensing,
M&A, & IPO.
EXIT
$10M/drug
(2X ROI) 
EXIT
$50M/drug
(5X ROI)
EXIT
$0.5B/drug
$0.3B/com.
(20X ROI)
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XII. Why Invest in NeuroNano Pharma?  
-9oneuro TM 14
1. Problem: Global obesity epidemics
2. Need: Delivery of leptin to the brain 
3. Solution:
leptiPOL™ HM - intranasal conjugated leptin 
formulation
4. Secured IP:
Over 30 patents and patent applications covering 
defined	regional	markets
5. Up to 20X ROI:
With $15M capital requirement up to 20X ROI in 
7-10 years
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XII. Thank you!
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Questions?
Please contact Z...
Zagit Gaymalov, Ph.D. 
zgaymalov@neuro10-9.com
+1.402.957.4290
www.neuro10-9.com
